Hsp27 (HSPB1): A possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas

Cell Stress and Chaperones

Volumn 17, Issue 6, 2012, Pages 779-790

  Castro, Gisela N ^a   Cayado Gutiérrez, Niubys ^a   Moncalero, Vera L ^b   Lima, Patricia ^c   De Angelis, Rodolfo Lucero ^c   Chávez, Victor ^c   Cuello Carrión, F Darío ^a   Ciocca, Daniel R ^a,d  

^a National Research Council   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c Neuro oncology Group   (Argentina)

^d INSTITUTO ARGENTINO DE NIVOLOGÍA   (Argentina)

Author keywords

1p status; Gliomas; Heat shock proteins; Molecular markers

Indexed keywords

BETA CATENIN; CYCLINE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BIOPSY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CHROMOSOME 1P; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOMA CELL; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BETA CATENIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 1; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGODENDROGLIOMA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84868115351     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-012-0350-6     Document Type: Article

References (43)

1. Berger AH, Knudson AG, Pandolfi PP (2011) A continuum model for tumour suppression. Nature 476:163-169. doi:10.1038/nature10275
2. Bignami M, O'Driscoll M, Aquilina G, Karran P (2000) Unmasking a killer: DNA O(6) methylguanine and the cytotoxicity of methylating agents. Mutat Res 462:71-82 (Pubitemid 30190215)
3. Calderwood SK, Khaleque A, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31:164-172 (Pubitemid 43361923)
4. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87:392-397 (Pubitemid 46474563)
5. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J (2007) Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol (Berl) 115:249-259
6. Cavenee WK, Furnari FB, Nagane M, Huang H, Newcomb EW, Bigner DD, Weller M, Berens ME, Plate KH, Israel MA, Noble MD, Kleihues P (2000) Diffusely infiltrating astrocytomas. In: Kleihues P, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, pp 15-21
7. Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25:1470-1475 (Pubitemid 46733073)
8. Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive and treatment implications. Cell Stress & Chaperones 10:86-103 (Pubitemid 40942470)
9. Coupland SE, Vorum H, Mandal N, Kalirai H, Honoré B, Urbak SF, Lake SL, Dopierala J, Damato B (2010) Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss. Invest Ophthalmol Vis Sci 51:12-20
10. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797 (Pubitemid 29086728)
11. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
12. Fanelli MA, Montt-Guevara M, Diblasi AM, Gago FE, Tello O, Cuello-Carrión FD, Callegary E, Bausero MA, Ciocca DR (2008) P-cadherin and β-catenin are useful prognostic markers in breast cancer patients; β-catenin interacts with heat shock protein Hsp27. Cell Stress and Chaperones 13:207-220
13. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14:121-130 (Pubitemid 38656383)
14. Gago FE, Tello OM, Diblasi AM, Ciocca DR (1998) Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. J Steroid Biochem Mol Biol 67:431-437 (Pubitemid 29049416)
15. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307 (Pubitemid 38525285)
16. Graner MW, Bigner DD (2005) Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro-Oncology 7:260-277 (Pubitemid 41079136)
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826 (Pubitemid 26296693)
18. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
19. Hitotsumatsu T, Iwaki T, Fukui M, Tateishi J (1996) Distinctive immunohistochemical profiles of small heat shock proteins (heat shock protein 27 and alpha B-crystallin) in human brain tumors. Cancer 77:352-361 (Pubitemid 26023355)
20. Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC (2009) Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study. Neuropathol Appl Neurobiol 35:367-379
21. Jha P, Sarkar C, Pathak P, Sharma MC, Kale SS, Gupta D, Chosdol K, Suri V (2011) Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: limitations and advantages in application to patient management. Diagn Mol Pathol 20:40-47
22. Jung TY, Jung S, Moon KS, Kim IY, Kang SS, Kim YH, Park CS, Lee KH (2010) Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep 5:1269-1276
23. Jung CS, Unterberg AW, Hartmann C (2011) Diagnostic markers for glioblastoma. Histol Histopathol 26:1327-1341
24. Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, Bruford EA, Chetham ME, Chen B, Hightower LE (2009) Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 14:105-111
25. Kim SH, Kim H, Kim TS (2005) Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors. Acta Neuropathol 110:27-38 (Pubitemid 41131194)
26. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, pp 33-49
27. Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW (2011) OMethylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 6:e17156
28. Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, Jenkins RB (2005) Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 160:1-14 (Pubitemid 40798130)
29. Liu C, Tu Y, Sun X, Jiang J, Jin X, Bo X, Li Z, Bian A,Wang X, Liu D, Wang Z, Ding L (2011) Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 11:105-112
30. Liu X, Wang L, Zhao S, Ji X, Luo Y, Ling F (2010) Beta-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Med Oncol 28:608-614
31. Louis D.N. and International Agency for Research on Cancer (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
32. Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177-183
33. Palmisano WA, Divine KK, Saccomanno G et al (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954-5958
34. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87:71-78
35. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63:1114-1121 (Pubitemid 36278446)
36. Pegg AE (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462:83-100
37. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M (2008a) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532
38. Preusser M, Elezi L, Hainfellner JA (2008b) Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 27:388-390
39. Preusser M (2009) MGMTanalysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 24:511-518
40. Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP (2009) Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int 55:307-317
41. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645 (Pubitemid 30078545)
42. Vassella E, Vajtai I, Bandi N, Arnold M, Kocher V, Mariani L (2010) Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. J Neurooncol 104:293-303
43. Wojdacz TK, Dobrovic A (2007) Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35:e41